ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017

Adjuvant Pazopanib Does Not PROTECT Against Recurrence of High-Risk, Initially Localized Renal Cell Cancer but Does Provide Novel Insights.

Grant D Stewart et al.PubMed ↗Publisher ↗

No numbers read from the abstract.